AB0261 Ongoing good response with biologics. data from the austrian biorg registry

Background The goal for the treatment of rheumatoid arthritis (RA) should be remission or at last low disease activity. Using data of the Austrian biologic registry we evaluated disease activity in patients with RA and treated with biologics for more than six years. Objectives The aim of this evaluation was to elucidate long term disease activity in patients with RA who are treated with a biologic. We checked data at baseline and at control-visits every six months after inclusion in BioReg. Methods Data were extracted from the Austrian BioReg registry (http://www.bioreg.at) which was initiated in 2009 to document patients treated with one of the biologics approved in Austria. Patients with ongoing biologic therapy as well as biologic-naive patients starting biologic therapy can be included (baseline, BL). Further documentation is recommended about every 6 months (V2, V2 up to V12). Until September 2017, 2132 patients (1157 RA, 497 SpA, 401 PsA, 77 other diseases) have been documented. Estimation of disease activity was done using DAS-28, RADAI-5, HAQ as well as ESR and CRP. Results DAS-28 (median values of BL; V2; V4; V10;V12) of our patients with RA are 3,30; 2,51; 2,33; 2,49; 2,58, the respective RADAI-5 values are 3,20; 2,20; 2,00; 2.00; 2,40 and values of HAQ are 0,75; 0,50; 0,50; 0,50; 0,63. Median values of inflammation’s laboratory markers (ESR in mm/1st hour and CRP in mg/l) were always within or close to the normal range (ESR and CRP in RA 15; 12; 11,5; 13,5; 11 and 2,1; 2,0; 2,0; 2,4; 3,0 Conclusions Our data confirm the efficiency of therapy with a biologic. During 6 years of continuous treatment more than half of the patients with RA are continuously in remission or low disease activity with a DAS-28 below 2,6, RADAI-5 equal or below to 2,40 and normal values of ESR and CRP. Acknowledgements BIOREG is supported by an unlimited industrial grant Disclosure of Interest None declared